MedTrace Logo

Transition of T1DM Patients Aged Over 65 Years Into AHCL (780G) Insulin Pump

NCT06207838 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-01-17

No results posted yet for this study

Summary

Older people with diabetes have a higher risk for cognitive impairment and for physical disability whether this may be effected by an improvement in glucose indices is unknown. Thus, the aim of this study is to assess the efficacy of AHCL in people with type 1 diabetes in improving glucose indices, quality of life and physical capacity indices

Conditions

  • Diabetes Type 1

Interventions

DEVICE

MiniMed 780G system

The MiniMed™ 780G system automatically adjust insulin delivery to patient needs for an easier way to stabilise glucose levels. It features an advance level of automation for diabetes management, known as SmartGuard™ technology. If patient glucose levels are trending high, it gives patient more insulin. Technology is CE marked.

Sponsors & Collaborators

  • Medtronic

    collaborator INDUSTRY

  • Jagiellonian University

    lead OTHER

Principal Investigators

  • Tomasz Klupa, Prof. · Jagiellonian University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-14
Primary Completion
2024-09-07
Completion
2024-12-31

Countries

  • Poland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06207838 on ClinicalTrials.gov